Literature DB >> 12834142

Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder.

Kenneth N Sokolski1, Thomas F Denson, Robert T Lee, Christopher Reist.   

Abstract

To assess the effects of adjunctive quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder (PTSD), charts of Vietnam veterans with war-connected PTSD who had been prescribed quetiapine were reviewed. Only patients with symptoms that had not responded to adequate therapy with two or more psychotropic medications prior to quetiapine treatment were analyzed. Addition of quetiapine to ongoing therapy resulted in further symptomatic improvements in DSM-IV PTSD criterion B (re-experiencing) for 35%, criterion C (avoidance/numbing) for 28%, and criterion D (arousal) for 65% of study subjects. Low doses of quetiapine (mean = 155 +/- 130 mg) were associated with minimal side effects. These results, although retrospective, suggest that augmentative quetiapine may benefit some refractory symptoms of PTSD in combat veterans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834142

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  8 in total

1.  Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents.

Authors:  Walter Alexander
Journal:  P T       Date:  2012-01

2.  Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features.

Authors:  Nela Pivac; Dragica Kozarić-Kovacić
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

3.  Use of antipsychotics in the treatment of post-traumatic stress disorder.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Kumar Budur; Manu Mathews; Jamal Mahmud; Thomas Osinowo
Journal:  Psychiatry (Edgmont)       Date:  2005-04

4.  Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters.

Authors:  Seth D Norrholm; Tanja Jovanovic
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

5.  Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.

Authors:  Damiaan Denys; André A Klompmakers; Herman G M Westenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-05-11       Impact factor: 4.530

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  Psychopharmacotherapy of posttraumatic stress disorder.

Authors:  Dragica Kozaric-Kovacic
Journal:  Croat Med J       Date:  2008-08       Impact factor: 1.351

8.  Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Authors:  Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.